Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lymphoma, T-Cell × Lenalidomide × Clear all

Phase

Status

Sponsor Class

OTHER 6 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 108 Recurrence 27 Lymphoma, Follicular 24 Lymphoma, Large B-Cell, Diffuse 22 Lymphoma, Non-Hodgkin 21 Neoplasms 12 Lymphoma, B-Cell, Marginal Zone 11 Leukemia, Lymphocytic, Chronic, B-Cell 10 Lymphoma 9 Lymphoma, Mantle-Cell 8 Hematologic Diseases 5 Neoplasms, Plasma Cell 3 Neoplasm Metastasis 3 Myelodysplastic Syndromes 3 Melanoma 3 Lymphoma, B-Cell 3 Leukemia, Myeloid, Acute 3 Hematologic Neoplasms 3 Pyloric Stenosis, Hypertrophic 2 Prostatic Neoplasms 2 Paraproteinemias 2 Ovarian Neoplasms 2 Leukemia, B-Cell 2 Bone Marrow Neoplasms 2 Wilms Tumor 1 Waldenstrom Macroglobulinemia 1 Vascular Diseases 1 Tumor Lysis Syndrome 1 Thromboembolism 1 Teratogenesis 1

Interventions

Brentuximab Vedotin 5 10-propargyl-10-deazaaminopterin 5 romidepsin 3 Cyclophosphamide 3 tenalisib 2 cobomarsen 2 belinostat 2 Vitamin B 12 2 Vincristine 2 Rituximab 2 Prednisone 2 Folic Acid 2 Doxorubicin 2 zanolimumab 1 tislelizumab 1 quisinostat 1 pembrolizumab 1 mogamulizumab 1 fostamatinib 1 forodesine 1 fludarabine 1 enzastaurin 1 enzalutamide 1 denileukin diftitox 1 darinaparsin 1 cc-486 1 Vorinostat 1 Solutions 1 Sensitivity and Specificity 1 ProMune 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00655668 2019-11-25

EXPECT

Celgene

Phase 2 Terminated

54 enrolled 13 charts

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡